Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study
AuthorsParry, M. G.
Cowling, T. E.
Patel, R. N.
Clarke, Noel W
van der Meulen, J.
AffiliationDepartment of Health Services Research and Policy, LSHTM; The National Prostate Cancer Audit, Clinical Effectiveness Unit, Royal College of Surgeons of England.
MetadataShow full item record
AbstractPurpose: External beam radiotherapy (EBRT) with brachytherapy boost reduces cancer recurrence in patients diagnosed with prostate cancer compared to EBRT monotherapy. However, randomised controlled trials or large-scale observational studies have not compared brachytherapy boost types directly. Methods and materials: This observational cohort study used linked national cancer registry data, radiotherapy data, administrative hospital data and mortality records of 54,642 patients diagnosed with intermediate-risk, high-risk and locally advanced prostate cancer in England. The records of 11,676 patients were also linked to results from a national patient survey collected at least 18 months after diagnosis. Competing risk regression analyses were used to compare gastrointestinal (GI) toxicity, genitourinary (GU) toxicity, skeletal-related events (SREs), and prostate cancer-specific mortality (PCSM) at five years with adjustment for patient and tumour characteristics. Linear regression was used to compare EPIC-26 domain scores (scale from 0 to 100, higher scores indicating better function). Results: 5-year GI toxicity was significantly increased after LDR-BB (32.3%) compared to HDR-BB (16.7%) or EBRT monotherapy (18.7%). 5-year GU toxicity was significantly increased after both LDR-BB (15.8%) and HDR-BB (16.6%), compared to EBRT monotherapy (10.4%). These toxicity patterns were matched by the mean patient-reported bowel function scores (LDR-BB: 77.3, HDR-BB: 85.8, and EBRT monotherapy: 84.4) and the mean patient-reported urinary obstruction/irritation function scores (LDR-BB: 72.2, HDR-BB: 78.9, and EBRT monotherapy: 83.8). 5-year incidences of SREs and PCSM were significantly lower after HDR-BB (2.4% and 2.7%, respectively) compared to EBRT monotherapy (2.8% and 3.5%, respectively). Conclusions: LDR-BB has worse GI and GU toxicity and HDR-BB has worse GU toxicity compared to EBRT monotherapy. HDR-BB has a lower incidence of SREs and PCSM than EBRT monotherapy.
CitationParry MG, Nossiter J, Sujenthiran A, Cowling TE, Patel RN, Morris M, et al. Impact of high-dose rate and low-dose rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study. Int J Radiat Oncol Biol Phys. 2020.
JournalInternational Journal of Radiation Oncology Biology Physics
- High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
- Authors: Yamazaki H, Masui K, Suzuki G, Nakamura S, Yamada K, Okihara K, Shiraishi T, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K
- Issue date: 2019 Mar
- Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
- Authors: Akimoto T, Ito K, Saitoh J, Noda SE, Harashima K, Sakurai H, Nakayama Y, Yamamoto T, Suzuki K, Nakano T, Niibe H
- Issue date: 2005 Oct 1
- Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
- Authors: Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W
- Issue date: 2019 Mar
- Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer.
- Authors: Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE
- Issue date: 2021 Jun 1
- A Brief Review of Low-Dose Rate (LDR) and High-Dose Rate (HDR) Brachytherapy Boost for High-Risk Prostate.
- Authors: Fischer-Valuck BW, Gay HA, Patel S, Baumann BC, Michalski JM
- Issue date: 2019